Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

被引：88

作者：

Hochmair, Maximilian J. ^{[1
]}

Morabito, Alessandro ^{[2
]}

Hao, Desiree ^{[3
]}

Yang, Cheng-Ta ^{[4
]}

Soo, Ross A. ^{[5
]}

Yang, James C-H ^{[6
,7
]}

Gucalp, Rasim ^{[8
]}

Halmos, Balazs ^{[8
]}

Wang, Lara ^{[9
]}

Golembesky, Amanda ^{[10
]}

Maerten, Angela ^{[11
]}

Cufer, Tanja ^{[12
]}

机构：

[1] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Dept Resp & Crit Care Med, Sanatoriumstr 2, A-1140 Vienna, Austria

[2] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, I-80131 Naples, Italy

[3] Univ Calgary, Cummings Sch Med, Tom Baker Canc Ctr, Calgary, AB, Canada

[4] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan

[5] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore

[6] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[7] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[8] Montefiore Albert Einstein, Canc Ctr, Dept Oncol, Bronx, NY USA

[9] Boehringer Ingelheim Taiwan Ltd, Clin Trials, Taipei, Taiwan

[10] Boehringer Ingelheim Int GmbH, Epidemiol, Ingelheim, Germany

[11] Boehringer Ingelheim Int GmbH, Med Affairs Oncol, Ingelheim, Germany

[12] Univ Ljubljana, Univ Clin Goln, Med Fac, Ljubljana, Slovenia

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 27期

关键词：

afatinib; osimertinib; NSCLC; sequential; T790M; 1ST-LINE TREATMENT; OPEN-LABEL; T790M MUTATION; SURVIVAL-DATA; ADENOCARCINOMA; GEFITINIB; CHEMOTHERAPY; EFFICACY; TKI;

D O I：

10.2217/fon-2018-0711

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials& methods: In this retrospective, observational, multicenter study, patients (n=204) had T790M-positive disease following first-line afatinib and started osimertinib treatment 10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors. Trial registration number: NCT03370770

引用

页码：2861 / 2874

页数：14

共 50 条

[1] Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
Hochmair, Maximilian J.
Morabito, Alessandro
Hao, Desiree
Yang, Cheng-Ta
Soo, Ross A.
Yang, James C-H
Gucalp, Rasim
Halmos, Balazs
Wang, Lara
Maerten, Angela
Cufer, Tanja
[J]. FUTURE ONCOLOGY, 2019, 15 (25) : 2905 - 2913
[2] Efficacy of afatinib following osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Tamura, Tomohiro
Okubo, Hatsumi
Yamada, Yutaka
Kikkawa, Yasuko
Yamaguchi, Shozaburo
Hashimoto, Ikuta
Kaburagi, Takayuki
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S335 - S335
[3] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
Alsharedi, M.
Bukamur, H.
Elhamdani, A.
[J]. DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
[4] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
Ramalingam, Suresh S.
Yang, James C-H
Lee, Chee Khoon
Kurata, Takayasu
Kim, Dong-Wan
John, Thomas
Nogami, Naoyuki
Ohe, Yuichiro
Mann, Helen
Rukazenkov, Yuri
Ghiorghiu, Serban
Stetson, Daniel
Markovets, Aleksandra
Barrett, J. Carl
Thress, Kenneth S.
Janne, Pasi A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
[5] Sequential treatment of afatinib followed by osimertinib in T790M EGFR mutation positive non-small-cell lung cancer (NSCLC) pa tients: an observational study
Hochmair, M.
Morabito, A.
Hao, D.
Yang, C. -T.
Soo, R. A.
Gucalp, R.
Halmos, B.
Wang, L.
Golembesky, A.
Maerten, A.
Cufer, T.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 75
[6] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
Meinrenken, Susanne
[J]. PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
[7] Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer
Bennouna, Jaafar
[J]. FUTURE ONCOLOGY, 2017, 13 (21) : 1829 - 1833
[8] Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
Carlisle, Jennifer W.
Ramalingam, Suresh S.
[J]. FUTURE ONCOLOGY, 2019, 15 (08) : 805 - 816
[9] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
Watanabe, Satomi
Hayashi, Hidetoshi
Nakagawa, Kazuhiko
[J]. ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
[10] Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Nobuyuki Yamamoto
Takeshi Mera
Angela Märten
Maximilian J. Hochmair
[J]. Advances in Therapy, 2020, 37 : 759 - 769

← 1 2 3 4 5 →